DK3260455T3 - Selektive pi3k delta-hæmmere - Google Patents

Selektive pi3k delta-hæmmere Download PDF

Info

Publication number: DK3260455T3
Authority: DK; Denmark
Prior art keywords: pi3k delta; selective pi3k; requests; delta requests; selective
Prior art date: 2012-07-04

Application number

DK17181585.5T

Other languages

English (en)

Inventor

Swaroop Kumar Venkata Satya Vakkalanka

Meyyappan Muthuppalaniappan

Dhanapalan Nagarathnam

Original Assignee

Rhizen Pharmaceuticals S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-04

Filing date

2013-07-02

Publication date

2019-06-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193752&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3260455(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-07-02 Application filed by Rhizen Pharmaceuticals S A filed Critical Rhizen Pharmaceuticals S A

2019-06-11 Application granted granted Critical

2019-06-11 Publication of DK3260455T3 publication Critical patent/DK3260455T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01137—Phosphatidylinositol 3-kinase (2.7.1.137)
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)

DK17181585.5T 2012-07-04 2013-07-02 Selektive pi3k delta-hæmmere DK3260455T3 (da)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
IN2692CH2012		2012-07-04
IN2693CH2012		2012-07-04
US201261691561P	2012-08-21	2012-08-21
US201261691586P	2012-08-21	2012-08-21
EP13744836.1A EP2870157B1 (en)	2012-07-04	2013-07-02	Selective pi3k delta inhibitors

Publications (1)

Publication Number	Publication Date
DK3260455T3 true DK3260455T3 (da)	2019-06-11

Family

ID=54193752

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK17181585.5T DK3260455T3 (da)	2012-07-04	2013-07-02	Selektive pi3k delta-hæmmere
DK13744836.1T DK2870157T3 (da)	2012-07-04	2013-07-02	Selektive pi3k delta-hæmmere

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK13744836.1T DK2870157T3 (da)	2012-07-04	2013-07-02	Selektive pi3k delta-hæmmere

Country Status (32)

Country	Link
US (7)	US9150579B2 (da)
EP (2)	EP2870157B1 (da)
JP (2)	JP6181173B2 (da)
KR (2)	KR102216606B1 (da)
CN (2)	CN104470923B (da)
AP (1)	AP2015008207A0 (da)
AR (1)	AR091677A1 (da)
AU (1)	AU2013285081B2 (da)
BR (1)	BR112014033055B1 (da)
CA (1)	CA2876995C (da)
CL (1)	CL2014003511A1 (da)
CO (1)	CO7170166A2 (da)
CY (2)	CY1119588T1 (da)
DK (2)	DK3260455T3 (da)
EA (1)	EA028750B1 (da)
ES (1)	ES2647416T3 (da)
HR (1)	HRP20171610T1 (da)
HU (1)	HUE034591T2 (da)
IL (1)	IL236351B (da)
LT (2)	LT2870157T (da)
MX (1)	MX357043B (da)
MY (1)	MY169987A (da)
PH (2)	PH12014502865B1 (da)
PL (2)	PL2870157T3 (da)
PT (1)	PT2870157T (da)
RS (2)	RS58793B1 (da)
SG (2)	SG11201408821SA (da)
SI (2)	SI2870157T1 (da)
SM (2)	SMT201900334T1 (da)
TW (1)	TWI598100B (da)
WO (1)	WO2014006572A1 (da)
ZA (2)	ZA201409329B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2779574C (en)	2009-11-05	2018-12-18	Rhizen Pharmaceuticals S.A.	Novel kinase modulators
AP4075A (en)	2011-05-04	2017-03-23	Rhizen Pharmaceuticals S A	Novel compounds as modulators of protein kinases
BR112014027470A2 (pt) *	2012-05-04	2017-06-27	Rhizen Pharmaceuticals S A	novo processo para preparação de derivados 2-(1-hidroxi-alquilo)-cromen-4-ona oticamente puros e opcionalmente substituídos e seu uso na preparação de produtos farmacêuticos.
US10130635B2 (en)	2012-05-04	2018-11-20	Rhizen Pharmaceuticals Sa	Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
DK3260455T3 (da) *	2012-07-04	2019-06-11	Rhizen Pharmaceuticals S A	Selektive pi3k delta-hæmmere
RS60844B1 (sr) *	2012-11-02	2020-10-30	Tg Therapeutics Inc	Kombinacija anti-cd20 antitela i selektivnog inhibitora pi3 kinaze
CA2914284A1 (en)	2013-05-30	2014-12-04	Infinity Pharmaceuticals, Inc.	Treatment of cancers using pi3 kinase isoform modulators
MX382033B (es)	2014-03-19	2025-03-13	Infinity Pharmaceuticals Inc	Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160986A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
EP3149000B1 (en)	2014-05-27	2021-06-30	Rhizen Pharmaceuticals S.A.	Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations
EP3160968B1 (en) *	2014-06-27	2018-10-31	Rhizen Pharmaceuticals S.A.	Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases
JP6291601B2 (ja)	2014-07-04	2018-03-14	ルピン・リミテッド	Ｐｉ３ｋ阻害剤としてのキノリジノン誘導体
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US10160761B2 (en)	2015-09-14	2018-12-25	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US20190070183A1 (en) *	2015-11-04	2019-03-07	The Trustees Of Columbia University In The City Of New York	Targeting Casein Kinase-1 and PI3K/AKT/mTOR Pathways for Treatment of c-Myc-Overexpressing Cancers, Organ Transplant Associated Complications and Autoimmune Diseases
WO2017156350A1 (en)	2016-03-09	2017-09-14	K-Gen, Inc.	Methods of cancer treatment
CA3019333C (en) *	2016-04-29	2024-01-02	Yuhan Corporation	Quinazoline derivative or its salt and pharmaceutical composition comprising the same
US10966977B2 (en)	2016-05-27	2021-04-06	Tg Therapeutics, Inc.	Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
RU2754507C2 (ru)	2016-06-24	2021-09-02	Инфинити Фармасьютикалз, Инк.	Комбинированная терапия
WO2018002958A1 (en)	2016-06-30	2018-01-04	Sun Pharma Advanced Research Company Limited	Novel hydrazide containing compounds as btk inhibitors
CN110191720A (zh)	2016-09-09	2019-08-30	Tg治疗有限公司	用于治疗血液学癌症的抗-CD20抗体、PI 3激酶-δ抑制剂以及抗-PD-1或抗-PD-L1抗体的组合
WO2019040102A1 (en)	2017-08-22	2019-02-28	Gilead Sciences, Inc.	THERAPEUTIC HETEROCYCLIC COMPOUNDS
CN108434150B (zh) *	2018-02-09	2020-03-10	天津医科大学总医院	Zstk474用于制备ean治疗药物的应用
AU2019297362B2 (en)	2018-07-06	2022-05-26	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
CA3104398A1 (en)	2018-07-06	2020-01-09	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
EP3828184A4 (en) *	2018-08-21	2022-05-04	Medshine Discovery Inc.	PYRAZOLOPYRIMIDI DERIVATIVES AND USE THEREOF AS A PI3K INHIBITOR
KR102866403B1 (ko) *	2019-06-27	2025-09-30	항저우 힐젠 테라퓨틱스 컴퍼니 리미티드	카세인 키나아제 1ε 억제제 및 약학 조성물 및 그 응용
EP3999511A1 (en) *	2019-07-15	2022-05-25	Johnson Matthey Public Limited Company	Amorphous umbralisib monotosylate
WO2021164789A1 (zh) *	2020-02-21	2021-08-26	南京明德新药研发有限公司	一种吡唑并嘧啶类化合物的晶型及其应用
US20220143026A1 (en)	2020-11-12	2022-05-12	Tg Therapeutics, Inc.	Triple combination to treat b-cell malignancies
CN114891005B (zh) *	2022-03-30	2024-01-19	武汉九州钰民医药科技有限公司	一种乌帕利斯对甲苯磺酸盐的制备工艺
US11807689B1 (en)	2022-06-01	2023-11-07	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11884740B1 (en)	2022-06-01	2024-01-30	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11814439B1 (en)	2022-06-01	2023-11-14	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11965032B1 (en)	2022-06-01	2024-04-23	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS62201882A (ja) *	1985-11-18	1987-09-05	Yamanouchi Pharmaceut Co Ltd	イソフラボン誘導体
JPH08176070A (ja)	1994-12-19	1996-07-09	Mitsubishi Chem Corp	ジデプシド誘導体及びｐｉ３キナーゼ阻害剤
JPH08175990A (ja)	1994-12-19	1996-07-09	Mitsubishi Chem Corp	Ｐｉ３キナーゼ阻害剤とその製造法
GB9521987D0 (en)	1995-10-26	1996-01-03	Ludwig Inst Cancer Res	Phosphoinositide 3-kinase modulators
JP2001247477A (ja)	2000-03-03	2001-09-11	Teikoku Hormone Mfg Co Ltd	抗腫瘍剤
ES2527754T3 (es)	2000-04-25	2015-01-29	Icos Corporation	Inhibidores de la isoforma delta de la fosfatidilinositol 3-quinasa humana
US6403588B1 (en)	2000-04-27	2002-06-11	Yamanouchi Pharmaceutical Co., Ltd.	Imidazopyridine derivatives
US6608053B2 (en)	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
ES2236481T3 (es)	2001-01-16	2005-07-16	Glaxo Group Limited	Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
EP1417976A4 (en)	2001-07-26	2004-09-15	Santen Pharmaceutical Co Ltd	AGENT FOR TREATING GLAUKOM WITH A COMPOUND WITH PI3-KINASE INHIBITING EFFECT
US6703414B2 (en)	2001-09-14	2004-03-09	Arizona Board Of Regents On Behalf Of The University Of Arizona	Device and method for treating restenosis
AU2002349912A1 (en)	2001-10-24	2003-05-06	Iconix Pharmaceuticals, Inc.	Modulators of phosphoinositide 3-kinase
AU2002357667A1 (en)	2001-10-24	2003-05-06	Iconix Pharmaceuticals, Inc.	Modulators of phosphoinositide 3-kinase
WO2003037886A2 (en)	2001-10-30	2003-05-08	Pharmacia Corporation	Heteroaromatic carboxamide derivatives for the treatment of inflammation
BR0309278A (pt) *	2002-04-17	2005-04-26	Cytokinetics Inc	Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
EP1531813A1 (en)	2002-07-10	2005-05-25	Applied Research Systems ARS Holding N.V.	Use of compounds for increasing spermatozoa motility
RS115904A (sr)	2002-07-10	2006-12-15	Applied Research Systems Ars Holding N.V.	Derivati benzena fuzionisani sa azolidinon vinilom
US20040092561A1 (en)	2002-11-07	2004-05-13	Thomas Ruckle	Azolidinone-vinyl fused -benzene derivatives
WO2004017950A2 (en)	2002-08-22	2004-03-04	Piramed Limited	Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US7601724B2 (en)	2002-09-04	2009-10-13	Schering Corporation	Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7605155B2 (en)	2002-09-04	2009-10-20	Schering Corporation	Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
RS20100366A (sr)	2002-12-16	2011-04-30	Genentech, Inc.	Varijante imunoglobulina i njihova upotreba
WO2004072029A2 (en)	2003-02-06	2004-08-26	Vertex Pharmaceuticals Incorporated	Pyrazolopyridazines useful as inhibitors of protein kinases
WO2004096135A2 (en)	2003-04-24	2004-11-11	Merck & Co., Inc.	Inhibitors of akt activity
AU2004263148B2 (en)	2003-08-06	2008-08-21	Vertex Pharmaceuticals, Incorporated	Aminotriazole compounds useful as inhibitors of protein kinases
US7501427B2 (en)	2003-08-14	2009-03-10	Array Biopharma, Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
US20050043239A1 (en)	2003-08-14	2005-02-24	Jason Douangpanya	Methods of inhibiting immune responses stimulated by an endogenous factor
US20060058311A1 (en)	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
US7608622B2 (en)	2004-09-24	2009-10-27	Janssen Pharmaceutica Nv	Imidazo[4,5-b]pyrazinone inhibitors of protein kinases
GB0423653D0 (en)	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
MY179032A (en)	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
FR2882751B1 (fr)	2005-03-04	2007-09-14	Aventis Pharma Sa	Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, procede de preparation, compositions les contenant et utilisation
JP2009500418A (ja)	2005-07-08	2009-01-08	メルクエンドカムパニーインコーポレーテッド	チェックポイントキナーゼの阻害剤
JP5016601B2 (ja)	2005-08-16	2012-09-05	アイアールエム・リミテッド・ライアビリティ・カンパニー	タンパク質キナーゼ阻害剤としての化合物および組成物
JP5002597B2 (ja)	2005-09-06	2012-08-15	スミスクラインビーチャムコーポレーション	ベンゾイミダゾールチオフェン化合物
GEP20115304B (en)	2005-10-07	2011-10-10	Exelixis Inc	PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
GB0520657D0 (en)	2005-10-11	2005-11-16	Ludwig Inst Cancer Res	Pharmaceutical compounds
US7790739B2 (en)	2005-10-21	2010-09-07	Merck & Co., Inc. and Merck Sharp & Dohme Corp.	Tyrosine kinase inhibitors
ES2389062T3 (es)	2006-01-18	2012-10-22	Amgen, Inc	Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
US20090233950A1 (en)	2006-03-02	2009-09-17	Frederic Henri Jung	Quinazoline derivatives
WO2007117995A2 (en)	2006-03-30	2007-10-18	Takeda San Diego, Inc.	Kinase inhibitors
EP2046799B1 (en)	2006-04-26	2017-07-19	Genentech, Inc.	Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
PT2024372E (pt)	2006-04-26	2010-09-16	Hoffmann La Roche	Derivado de tieno[3,2-d]pirimidina útil como inibidor de pi3k
US20090239936A1 (en)	2006-05-15	2009-09-24	Yoshikazu Sugimoto	Prophylactic and Therapeutic Agent for Cancer
GB0610243D0 (en)	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
US20090263398A1 (en)	2006-07-14	2009-10-22	Astex Therapeutics Limited	Pharmaceutical combinations
EP2049542B1 (en)	2006-08-09	2012-09-19	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
WO2008032072A1 (en)	2006-09-14	2008-03-20	Astrazeneca Ab	2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
RU2470936C2 (ru)	2006-12-07	2012-12-27	Дженентек, Инк.	Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
MY180595A (en)	2006-12-07	2020-12-03	Genentech Inc	Phosphoinositide 3-kinase inhibitor compounds and methods of use
PE20090288A1 (es)	2007-05-10	2009-04-03	Smithkline Beecham Corp	Derivados de quinoxalina como inhibidores de la pi3 quinasa
JP2010532758A (ja)	2007-07-06	2010-10-14	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	組み合わせ抗癌療法
ATE551342T1 (de)	2008-02-22	2012-04-15	Irm Llc	Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer
EP2259678A4 (en)	2008-02-29	2011-07-27	Cylene Pharmaceuticals Inc	PROTEIN KINASE MODULATORS
AP2651A (en)	2008-03-04	2013-04-25	Natco Pharma Ltd	Crystal form of phenylamino pyrimidine derivatives
US20090227575A1 (en)	2008-03-04	2009-09-10	Wyeth	7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
CN102015719A (zh)	2008-03-06	2011-04-13	百时美施贵宝公司	吡咯并三嗪激酶抑制剂
UY31700A (es)	2008-03-13	2009-11-10	Boehringer Ingelheim Int	Tiazolil-dihidro-indazoles
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
WO2009114874A2 (en) *	2008-03-14	2009-09-17	Intellikine, Inc.	Benzothiazole kinase inhibitors and methods of use
US8822500B2 (en) *	2008-03-19	2014-09-02	Chembridge Corporation	Tyrosine kinase inhibitors
KR20110017845A (ko)	2008-03-19	2011-02-22	오에스아이 파마슈티컬스, 인코포레이티드	Ｍｔｏｒ 억제자 염 형태
EP2966076A1 (en)	2008-03-19	2016-01-13	ChemBridge Corporation	Novel tyrosine kinase inhibitors
US8268834B2 (en)	2008-03-19	2012-09-18	Novartis Ag	Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US20110053907A1 (en)	2008-03-27	2011-03-03	Auckland Uniservices Limited	Substituted pyrimidines and triazines and their use in cancer therapy
ES2480994T3 (es)	2008-03-31	2014-07-29	Genentech, Inc.	Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
US20090258907A1 (en)	2008-04-09	2009-10-15	Abbott Laboratories	Compounds useful as inhibitors of rock kinases
MX2010011370A (es)	2008-04-16	2010-12-15	Vertex Pharma	Inhibidores de fosfatidilinositol 3-cinasa.
JP2011518171A (ja)	2008-04-16	2011-06-23	武田薬品工業株式会社	５−（３−（エチルスルホニル）フェニル）−３，８−ジメチル−ｎ−（１−メチルピペリドン−４−イル）−９ｈ−ピリド［２，３−ｂ］インドール−７−カルボキサミドの多形およびその使用方法
AU2009313878B2 (en)	2008-11-13	2016-01-07	Gilead Calistoga Llc	Therapies for hematologic malignancies
MX2011009955A (es)	2009-03-24	2011-11-18	Gilead Calistoga Llc	Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso.
EP2421536B1 (en)	2009-04-20	2015-08-26	Gilead Calistoga LLC	Methods of treatment for solid tumors
CA2779574C (en)	2009-11-05	2018-12-18	Rhizen Pharmaceuticals S.A.	Novel kinase modulators
AP4075A (en) *	2011-05-04	2017-03-23	Rhizen Pharmaceuticals S A	Novel compounds as modulators of protein kinases
DK3260455T3 (da) *	2012-07-04	2019-06-11	Rhizen Pharmaceuticals S A	Selektive pi3k delta-hæmmere

2013
- 2013-07-02 DK DK17181585.5T patent/DK3260455T3/da active
- 2013-07-02 MY MYPI2014003647A patent/MY169987A/en unknown
- 2013-07-02 RS RS20190687A patent/RS58793B1/sr unknown
- 2013-07-02 BR BR112014033055-7A patent/BR112014033055B1/pt not_active IP Right Cessation
- 2013-07-02 CN CN201380035108.8A patent/CN104470923B/zh not_active Expired - Fee Related
- 2013-07-02 CA CA2876995A patent/CA2876995C/en active Active
- 2013-07-02 SG SG11201408821SA patent/SG11201408821SA/en unknown
- 2013-07-02 HR HRP20171610TT patent/HRP20171610T1/hr unknown
- 2013-07-02 LT LTEP13744836.1T patent/LT2870157T/lt unknown
- 2013-07-02 KR KR1020197015824A patent/KR102216606B1/ko not_active Expired - Fee Related
- 2013-07-02 JP JP2015519472A patent/JP6181173B2/ja not_active Expired - Fee Related
- 2013-07-02 CN CN201910154523.4A patent/CN109970742A/zh active Pending
- 2013-07-02 KR KR1020157001057A patent/KR101988079B1/ko not_active Expired - Fee Related
- 2013-07-02 SI SI201330819T patent/SI2870157T1/en unknown
- 2013-07-02 HU HUE13744836A patent/HUE034591T2/en unknown
- 2013-07-02 PT PT137448361T patent/PT2870157T/pt unknown
- 2013-07-02 RS RS20171141A patent/RS56494B1/sr unknown
- 2013-07-02 DK DK13744836.1T patent/DK2870157T3/da active
- 2013-07-02 EA EA201492176A patent/EA028750B1/ru unknown
- 2013-07-02 EP EP13744836.1A patent/EP2870157B1/en active Active
- 2013-07-02 PL PL13744836T patent/PL2870157T3/pl unknown
- 2013-07-02 US US13/933,856 patent/US9150579B2/en active Active - Reinstated
- 2013-07-02 ES ES13744836.1T patent/ES2647416T3/es active Active
- 2013-07-02 AP AP2015008207A patent/AP2015008207A0/xx unknown
- 2013-07-02 EP EP17181585.5A patent/EP3260455B1/en active Active
- 2013-07-02 LT LTEP17181585.5T patent/LT3260455T/lt unknown
- 2013-07-02 SG SG10201704048UA patent/SG10201704048UA/en unknown
- 2013-07-02 WO PCT/IB2013/055434 patent/WO2014006572A1/en not_active Ceased
- 2013-07-02 SM SM20190334T patent/SMT201900334T1/it unknown
- 2013-07-02 PL PL17181585T patent/PL3260455T3/pl unknown
- 2013-07-02 SI SI201331473T patent/SI3260455T1/sl unknown
- 2013-07-02 AU AU2013285081A patent/AU2013285081B2/en not_active Ceased
- 2013-07-02 MX MX2014015946A patent/MX357043B/es active IP Right Grant
- 2013-07-02 SM SM20170560T patent/SMT201700560T1/it unknown
- 2013-07-03 TW TW102123806A patent/TWI598100B/zh not_active IP Right Cessation
- 2013-07-05 AR ARP130102394 patent/AR091677A1/es not_active Application Discontinuation
2014
- 2014-12-18 IL IL236351A patent/IL236351B/en active IP Right Grant
- 2014-12-18 ZA ZA2014/09329A patent/ZA201409329B/en unknown
- 2014-12-22 PH PH12014502865A patent/PH12014502865B1/en unknown
- 2014-12-23 CL CL2014003511A patent/CL2014003511A1/es unknown
2015
- 2015-01-15 CO CO15007491A patent/CO7170166A2/es unknown
- 2015-08-21 US US14/832,962 patent/US9475818B2/en not_active Expired - Fee Related
- 2015-10-09 ZA ZA2015/07539A patent/ZA201507539B/en unknown
2016
- 2016-01-22 PH PH12016500156A patent/PH12016500156A1/en unknown
- 2016-10-03 US US15/283,515 patent/US9669033B2/en not_active Expired - Fee Related
2017
- 2017-04-05 US US15/480,128 patent/US10072013B2/en active Active
- 2017-07-19 JP JP2017139758A patent/JP6416339B2/ja not_active Expired - Fee Related
- 2017-11-10 CY CY20171101179T patent/CY1119588T1/el unknown
2018
- 2018-08-22 US US16/109,337 patent/US10570142B2/en active Active
2019
- 2019-06-03 CY CY20191100585T patent/CY1121793T1/el unknown
2020
- 2020-01-29 US US16/776,327 patent/US10981919B2/en not_active Expired - Fee Related
2021
- 2021-04-01 US US17/220,806 patent/US20210403475A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PH12014502865A1 (en)	2015-02-23
CY1119588T1 (el)	2018-03-07
EA201492176A1 (ru)	2015-08-31
AU2013285081A1 (en)	2015-01-22
US20150361083A1 (en)	2015-12-17
CN104470923A (zh)	2015-03-25
CN109970742A (zh)	2019-07-05
CN104470923B (zh)	2019-03-29
DK2870157T3 (da)	2017-11-06
MY169987A (en)	2019-06-19
US20200270258A1 (en)	2020-08-27
US20190194206A1 (en)	2019-06-27
SG11201408821SA (en)	2015-01-29
BR112014033055B1 (pt)	2023-01-31
CL2014003511A1 (es)	2015-07-10
US20210403475A1 (en)	2021-12-30
MX357043B (es)	2018-06-25
ES2647416T3 (es)	2017-12-21
EP3260455A1 (en)	2017-12-27
KR20190064687A (ko)	2019-06-10
MX2014015946A (es)	2015-07-17
PH12016500156B1 (en)	2017-04-10
BR112014033055A2 (pt)	2017-06-27
AP2015008207A0 (en)	2015-01-31
US9475818B2 (en)	2016-10-25
HK1209737A1 (en)	2016-04-08
IL236351A0 (en)	2015-02-26
PH12014502865B1 (en)	2015-02-23
KR102216606B1 (ko)	2021-02-17
RS58793B1 (sr)	2019-07-31
BR112014033055A8 (pt)	2021-09-08
IL236351B (en)	2018-01-31
US20170204105A1 (en)	2017-07-20
US9150579B2 (en)	2015-10-06
TW201402123A (zh)	2014-01-16
JP2017186378A (ja)	2017-10-12
ZA201507539B (en)	2017-01-25
CY1121793T1 (el)	2020-07-31
CA2876995A1 (en)	2014-01-09
US20170020881A1 (en)	2017-01-26
EP2870157A1 (en)	2015-05-13
KR101988079B1 (ko)	2019-06-11
US10072013B2 (en)	2018-09-11
SMT201700560T1 (it)	2018-01-11
SMT201900334T1 (it)	2019-07-11
ZA201409329B (en)	2016-08-31
WO2014006572A1 (en)	2014-01-09
US10570142B2 (en)	2020-02-25
PL2870157T3 (pl)	2018-01-31
CO7170166A2 (es)	2015-01-28
SG10201704048UA (en)	2017-06-29
HUE034591T2 (en)	2018-02-28
AU2013285081B2 (en)	2017-01-12
PT2870157T (pt)	2017-11-27
PH12016500156A1 (en)	2017-04-10
JP6181173B2 (ja)	2017-08-16
HRP20171610T1 (hr)	2018-03-23
TWI598100B (zh)	2017-09-11
SI2870157T1 (en)	2018-02-28
AR091677A1 (es)	2015-02-18
US20140011819A1 (en)	2014-01-09
US10981919B2 (en)	2021-04-20
CA2876995C (en)	2020-10-06
PL3260455T3 (pl)	2019-12-31
JP2015522009A (ja)	2015-08-03
LT2870157T (lt)	2017-12-11
RS56494B1 (sr)	2018-01-31
JP6416339B2 (ja)	2018-10-31
KR20150036083A (ko)	2015-04-07
LT3260455T (lt)	2019-06-10
US9669033B2 (en)	2017-06-06
SI3260455T1 (sl)	2019-07-31
EA028750B1 (ru)	2017-12-29
EP2870157B1 (en)	2017-08-30
EP3260455B1 (en)	2019-03-20

Publication	Publication Date	Title
DK3260455T3 (da)	2019-06-11	Selektive pi3k delta-hæmmere
DK2863961T3 (da)	2019-01-02	Hæmostatiske indretninger
BR112015011600A2 (pt)	2017-07-11	dispositivo
IL231351A0 (en)	2014-04-30	Amino-substituted imidazopyridazines
BR112015008649A2 (pt)	2017-08-22	Aparelho
EP2860233A4 (en)	2016-06-01	PUNCTURE CLOSURE MEANS
JP2012186158A5 (ja)	2015-03-19	製造装置
DE112013005825A5 (de)	2015-10-29	Reduktionsmittelzuführeinrichtung
ES1078393Y (es)	2013-04-10	Dispositivo masturbador
DK2919725T3 (da)	2019-07-01	Vasodilatationsindretning
JP2012158832A5 (ja)	2014-11-27	製造装置
DE112013001653A5 (de)	2014-12-18	Carben-Übertragungsreagenz
UA25745S (uk)	2013-11-11	Зупинковий комплекс
HUE045210T2 (hu)	2019-12-30	Szelektív PI3K delta inhibitorok
BR302012004846S1 (pt)	2014-05-27	Configuracao aplicada em bufê
TH1401005346B (th)	2016-02-15	ที่วางแขน
ES1076176Y (es)	2012-05-14	Dispositivo porta-biberon
UA24070S (uk)	2012-12-10	Ніж
BR302012005759S1 (pt)	2014-05-27	Configuração aplicada em arandela
BR302012005732S1 (pt)	2014-10-29	Configuração aplicada em tamanco
BR302012005615S1 (pt)	2014-06-03	Configuração aplicada em arandela
BR302012005617S1 (pt)	2014-05-27	Configuração aplicada em arandela
BR302012005616S1 (pt)	2014-05-27	Configuração aplicada em arandela
BR302012005100S1 (pt)	2014-06-03	Configuracao aplicada em chinelo
BR302012005102S1 (pt)	2014-10-29	Configuracao aplicada em chinelo